Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04566653 · ClinicalTrials.gov registry record
Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 147
- Enrollment target
NCT04566653 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 147 participants.
The verdict
NCT04566653 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 147 participants
- Enrollment target
Study Summary
This non-interventional, Phase IV, exploratory, cross-over, randomised, single-blind, active comparator-controlled study has been designed to measure the palatability and preference of Lokelma® versus Veltassa® versus S/CPS in patients with dialysis and non-dialysis chronic kidney disease (CKD) and hyperkalaemia (HK). The sponsor hypothesizes that palatability, in terms of taste, texture, smell, and mouthfeel, will score higher (better) for Lokelma when compared with Veltassa and S/CPS.
Interventions
- DRUG Calcium Polystyrene Sulphonate 15g/60 mL water
- DRUG Lokelma® 5 g/45mL water
- DRUG Lokelma® 10 g/45 mL water
- DRUG Veltassa® 8,4 g/80mL water
- DRUG Sodium Polystyrene Sulphonate 15g/60 mL water
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2020-10-23 |
| Est. Completion | 2022-01-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04566653
The ClinicalTrials.gov registry entry for NCT04566653 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Calcium Polystyrene Sulphonate 15g/60 mL water is the first listed.
NCT04566653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04566653 about?
NCT04566653 is a clinical study titled "Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia". This non-interventional, Phase IV, exploratory, cross-over, randomised, single-blind, active comparator-controlled study has been designed to measure the palatability and preference of Lokelma® versus Veltassa® versus S/CPS in patients with dialysis and non-dialysis chronic kidney disease (CKD) and ...
What is the current status of trial NCT04566653?
This trial is currently completed. The enrollment target is 147 participants. The study started on 2020-10-23. Estimated completion is 2022-01-12.
What interventions are being tested in trial NCT04566653?
The interventions under investigation include: Calcium Polystyrene Sulphonate 15g/60 mL water (DRUG), Lokelma® 5 g/45mL water (DRUG), Lokelma® 10 g/45 mL water (DRUG), Veltassa® 8,4 g/80mL water (DRUG), Sodium Polystyrene Sulphonate 15g/60 mL water (DRUG).
Who is sponsoring clinical trial NCT04566653?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.